Monika Schafer-Korting
Executive Vice President
Freie University Berlin
Germany
Biography
Monika SCHÄFER-KORTING is awarded PhD in pharmacology from Goethe-Universität, Frankfurt in the year 1977. She holds a Master Degree in Pharmacy studies, from Goethe University, Frankfurt in the year 1975. She has extended her valuable service as an Executive Vice President of Freie Universität Berlin from 2010 – present, and has been working as a Full professor (C4) of pharmacology, Institute of Pharmacy, Freie Universität Berlin from 1994 – present and has been a recipient of many award and grants. Currently, he/she is working as an President for Freie Universität Berlin. Her international experience includes various programs, contributions and participation in different countries for diverse fields of study. Her research interests reflect in her wide range of publications in various national and international journals. She serves as a member of various associations Member of the BMBF research group, Member of the BMBF research group apart from being an author of many publications.
Research Interest
The focus is on the improvement of the therapy of skin diseases by testing potential new pharmaceuticals with regard to the skin, elucidating the molecular mechanisms of action of known and new drugs, investigating the uptake and metabolization of such substances in human skin, but also with the aid of two- and three-dimensional skin models Models of skin diseases and an increase in the benefit / risk ratio by means of particulate carrier systems. Pharmacokinetic experiments also show a significant contribution to the metabolism of these drugs in the skin for the differences in the benefit / risk ratio. It is precisely these studies that point to the particular importance of the still widely unknown skin metabolism. After clinical studies with a liposomal glucocorticoid have already pointed out progress by particulate carrier systems, systematic investigations are now being carried out on the skin-specific drug application by means of complex carrier systems.
Biography
Jürgen Borlak was born in Neu-Ulm, Germany in 1958. After studies at Universities in Germany and abroad he obtained his Doctorate in Pharmacology and Toxicology at the University of Reading, GB. Following residencies in the UK and France (Strasbourg) he was habilitated in pharmacology and toxicology and received the venia legendi (“Privatdozentâ€) at Hannover Medical School in the year 2000. Two years later he was appointed as full professor of Pharmacology and Toxicology at Hannover Medical School. From 2002 onwards he has been the Director of the Institute of Pharmaco- and Toxicogenomics at Hannover Medical School. This new field of genomic science applies a wide range of methods in genetics, molecular biology, molecular toxicology and functional genomics for a better understanding of disease causing mechanisms and drug induced toxicities. An array of enabling technologies are applied for an identification of “drugable†targets and for a better understanding of inter-individual differences in drug response, therefore allowing individualized drug treatment regimens and disease prevention strategies. Jürgen Borlak is also an appointed Professor of Molecular Anatomy at the Medical Faculty of the University Leipzig; a Professor of Experimental Medicine at Uppsala University, Sweden and is Distinguished Visiting Professor at the University of Trento, Italy. Jürgen Borlak is author of > 270 original publications and 25 book chapters and editor of the Handbook of Toxicogenomics. He is reviewer and member of the editorial board for various scientific journals. Amongst others he is an appointed expert of the World Health Organisation (WHO), of the US governmental agency FDA, the European Medicines Agency EMA and is also an international reviewer for many European, US and Asian Research Organisations.
Research Interest
Pharmacology, Toxicology
Alexei G. Basnakian
Professor
University of Arkansas for Medical Sciences, Little Rock
USA
Biography
Alexei Basnakian had received his M.D. from Sechenov Moscow Medical School, and Ph.D. and D.Sc. degrees from the Russian Academy of Medical Science, both in the field of biochemistry. He had postdoctoral trainings in molecular biology at the Harvard Medical School and in toxicology/cancer research at the National Center for Toxicological Research, Food and Drug Administration, USA. Dr. Basnakian is a tenured Professor in the Department of Pharmacology and Toxicology, and Director of the DNA Damage and Toxicology Core Center at the University of Arkansas for Medical Sciences, and Research Career Scientist at the Veteran’s Hospital in Little Rock, Arkansas, USA. He is an author of more than 85 peer-reviewed papers and 12 reviews or book chapters. Dr. Basnakian is an Editorial Board member of three biomedical journals, and a member of NIH, AHA and VA grant study sections. His research interests are drug discovery in the field of DNA endonucleases and DNA damage associated with toxicity, tissue injury and cell death.
Research Interest
DNA endonucleases and DNA damage associated with toxicity, anti-cancer therapy, cell injury and cell death.
